Cargando…
Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma
BACKGROUND: Patients with common variable immunodeficiency (CVID) have an increased risk of developing lymphoproliferative diseases, including non-Hodgkins lymphoma (Blood 116:1228–1234, 2010; Blood 119:1650–7, 2012). The incidence and prognosis of Hodgkin lymphoma in this population is not clear, w...
Autores principales: | Rael, Efren, Rakszawski, Kevin, Koller, Kristian, Bayerl, Michael, Butte, Manish, Zheng, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785670/ https://www.ncbi.nlm.nih.gov/pubmed/26966541 http://dx.doi.org/10.1186/s40364-016-0061-8 |
Ejemplares similares
-
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019) -
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013) -
Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)